<p>You are about to enter the B. Braun Melsungen AG (global) website. If you are from United States, visit the U. S. Website</p>

United States - B. Braun Medical Inc.

Global - B. Braun Melsungen AG

<p>Not all products are registered and approved for sale in all countries or regions. Indications of use may also vary by country and region. Please contact your country representative for product availability and information. Product images are for reference only.</p>

You have successfully logged out.

BASKET-SMALL 2

BASKET-SMALL 2 (3-year data available – October 2020)

Basel Stent Kosten Effektivitäts Trial Drug Coated Balloons vs. Drug Eluting Stents in Small Vessel Interventions

_{Jeger R et al. The Lancet, August 2018.}

_{Trial Registration Number: NCT01574534 on https://www.clinicaltrials.gov}

_{Jeger R et al. The Lancet, October 2020. Same trial registration.}

Key findings

Largest randomized clinical trial with primary clinical endpoint, testing the efficacy of SeQuent® Please NEO (DCB) vs. 2^nd generation DES for the treatment of small vessel coronary artery disease.
DCB-only treatment with SeQuent® Please NEO achieves clinical results comparable to 2^nd generation DES implantation in de novo lesions up to 3 mm in reference vessel diameter.

Description

Indication: Ischemic coronary artery disease (CAD) in native de novo lesions

Main inclusion criteria:

Vessel diameter ≥ 2 mm to < 3 mm
Native vessel
Successful pre-dilation according to consensus recommendations for DCB-usage

Primary outcome:

MACE @ 12 months (MACE includes: TVR, non-fatal MI, cardiac death)
MACE @ 36 months (MACE includes: TVR, non-fatal MI, cardiac death)

Secondary outcomes:

TVR, non-fatal MI, cardiac death, stent thrombosis, bleeding

Dual Antiplatelet Therapy (DAPT):

4 weeks of DAPT in stable patients treated with DCB or 6 months for DES. In patients with acute coronary syndrome (ACS) 12-month DAPT

Results

758 patients randomized after pre-dilation (86 % of 883 initially assessed patients)

382 assigned for DCB-treatment, 376 for DES-treatment
Well-balanced demographic and procedural parameters between the treatment groups

Primary outcome: No statistical difference between groups

MACE @ 12 months 7.3% in the DCB group vs. 7.5% in the DES group (p=0.92)
The primary endpoint was met for non-inferiority at both time points (DCB not worse than DES)

Secondary outcome:

MACE @ 36 months 15% in both groups (p=0.95)
@ 12 months DCB vs. DES – cardiac death: 3.1 vs. 1.3 %, MI 1.6 vs. 3.5 % or TVR 3.4 vs. 4.5%
@ 36 months DCB vs. DES – cardiac death: 5 vs. 4 %, MI 6 vs. 6 % or TVR 9 vs. 9%

Other endpoints:

@ 12 months: Probable or definite thrombosis were low and comparable between DCB and DES patients (0.79 vs. 1.60 %). Rates of major bleeding were low and similar in DCB and DES patients (1.1 vs. 2.4 %).
@ 36 months: Probable or definite thrombosis (1% in DCB and 2% in DES, p=0.18). Rates of major bleeding (2% in DCB vs. 4% in DES, p=0.088) were numerically lower in the DCB group without statistical significance.

Conclusion

BASKET SMALL 2 is the largest randomized trial with primary clinical endpoint comparing DCB with 2^nd generation DES in small vessel coronary artery disease – DCB is non-inferior to 2^nd generation DES in the treatment of SVD.